KEY FACTS
Terminology
- •
Malignant tumor of transitional epithelium extending from calyces to ureteral orifices
- •
a.k.a. transitional cell carcinoma
Imaging
- •
Hypoechoic infiltrative tumor in renal pelvis or ureter
- •
Wall thickening or intraluminal soft tissue mass
- •
Papillary or sessile mass
- •
Secondary hydronephrosis and calyceal dilatation
- •
Advanced tumor: Diffusely infiltrating renal mass, invading sinus fat but with preservation of renal contour
- •
Hypovascular on color Doppler
- •
CT or MR with contrast superior to US for diagnosis and staging
- •
MRU: Alternative to CTU in patients with iodinated contrast allergy
- •
Contrast-enhanced US may be option in patients unable to have enhanced CT or MR but limited for staging
Top Differential Diagnoses
- •
Renal cell carcinoma
- •
Lymphoma
- •
Blood clot or hemonephrosis
- •
Other causes of obstruction or urothelial thickening
Pathology
- •
10% of all renal tumors: Renal pelvis: 8%; ureter: 2%
- •
Multifocality with synchronous and metachronous tumors; most common in bladder
- •
Highest recurrence rate of any cancer
- •
Risk factors include: Tobacco use, chemical carcinogens, recurrent urinary infections and stones
Clinical Issues
- •
Gross or microscopic hematuria (70-80%), flank pain (20-40%), lumbar mass (10-20%)
- •
Peak incidence: 70-80 years (M:F = 3:1)
- •
Most common sites of recurrence for upper tract urothelial carcinoma include bladder (22-47%) and contralateral collecting system (2-6%)
Scanning Tips
- •
Look for upper tract lesions in setting of bladder cancer
- •
Use color Doppler to differentiate tumor from clot/debris
- •
Follow dilated collecting system to point of transition and look for pathology there